Ninlaro (Ixazomib Citrate) Patent Expiration, LOE Window & CMS Spending
Ninlaro (Ixazomib Citrate) by Takeda: FDA Orange Book core substance LOE 2029-11-20, 0 AB generics, $282.6M 2024 CMS Part D & Medicaid spend, and 26 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N208462 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-11-20 |
| Last Listed Patent or Exclusivity Date | 2029-11-20 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $282.6M |
| 2024 Medicare Part D Spend | $272.7M |
| 2024 Medicaid Spend | $9.9M |
| Reported Wholesale Price Change (CA SB 17) | 26 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.